Department of Neurosurgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
J Clin Neurosci. 2009 Dec;16(12):1615-8. doi: 10.1016/j.jocn.2009.05.007. Epub 2009 Oct 12.
This study was performed to determine the relationship between p57/Kip2 and the growth of human astrocytomas. Immunohistochemical staining for p57/Kip2, p53, p16, and Ki67 antigen was performed on paraffin-embedded tissue specimens obtained from 36 patients with astrocytoma. Expression of p57/Kip2, p53, p16, and Ki67 antigen was generally increased in association with the astrocytoma tumor grade. Expression of p16 was higher in patients whose tumors express p57/Kip2 in greater than 10% of tumor cells (p<0.05). Expression of p53 also tended to be higher, but not to a statistically significant extent, in patients whose tumors express p57/Kip2 in greater than 10% of tumor cells. These findings suggest that p57/Kip2 inhibits the growth of human astrocytomas, and may function in parallel with p16 and p53. However, p57/Kip2 is, by itself, insufficient to arrest the cellular proliferation of human astrocytomas.
本研究旨在探讨 p57/Kip2 与人类星形细胞瘤生长之间的关系。我们对 36 例星形细胞瘤患者的石蜡包埋组织标本进行了 p57/Kip2、p53、p16 和 Ki67 抗原的免疫组织化学染色。p57/Kip2、p53、p16 和 Ki67 抗原的表达通常与星形细胞瘤的肿瘤分级相关,随着肿瘤分级的增加而增加。在肿瘤细胞中 p57/Kip2 表达大于 10%的患者中,p16 的表达更高(p<0.05)。p53 的表达也有升高的趋势,但没有达到统计学显著水平。这些发现表明 p57/Kip2 抑制了人类星形细胞瘤的生长,可能与 p16 和 p53 平行发挥作用。然而,p57/Kip2 本身不足以阻止人类星形细胞瘤的细胞增殖。